Loading clinical trials...

UNKNOWN

Alternations of Intestinal Microbiota and Health Impact in CKD

Alternations of Intestinal Microbiota and Health Impact in Chronic Kidney Disease (AIM-HI CKD): A Cohort Study

NCT03794401•Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation

Summary

This study is aimed to evaluate the impact of dietary pattern, gut microbiota and their interactions on clinical outcomes among patient with CKD stage 3-5.

Eligibility

Age

20 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients with CKD stage 3-5 defined as eGFR \<60 ml/min/1.73 m2 calculated with the use of the four-variable Modification of Diet in Renal Disease formula who have not yet on dialysis therapy.

Exclusion Criteria

•Patients with active cancer
•Patients with liver cirrhosis
•Patients have taken antibiotics within three months before screening for inclusion.
•Patients with a cardiac pacemaker or metallic implants,
•Patients are amputees
•Pregnant women
•Patients with inherited renal diseases

Locations (1)

Taipei Tzu Chi Hospital

New Taipei City, Taiwan

Key Dates

Start Date

April 1, 2019

Primary Completion Date

June 30, 2023

Completion Date

June 30, 2023

Last Updated

March 2, 2022

Enrollment

750

ESTIMATED participants

Conditions

Chronic Kidney Disease

Contacts

TING-YUN LIN

CONTACT

+886-2-66289779 water_h2o_6@hotmail.com

A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

NCT07241390

Atherosclerosis Cardiovascular DiseaseChronic Kidney Disease

View study

RECRUITINGPHASE2

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease

NCT06926660

Chronic Kidney Disease

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 2, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Alternations of Intestinal Microbiota and Health Impact in CKD

Inclusion Criteria

Exclusion Criteria

A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease

A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

OPTIMISE-CKD Study_Dapagliflozin Effectiveness in CKD

Human Amniotic-Derived Mesenchymal Stem Cell Therapy for Calciphylaxis

Prevalence of Gastric Motor Dysfunction and Upper GI Symptoms in Gastric Antral Vascular Ectasias